Drug Patent Watch

OCTOBER 12, 2021

International License Abstract Development of generic drug product…. The post Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review appeared first on DrugPatentWatch - Make Better Decisions. This paper was originally published by Md.

Production 105

Production Pharmaceuticals Licensing Licensing 105

The Pharma Data

JANUARY 6, 2021

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

Licensing 52

Licensing Licensing Therapies Pharmaceutical Companies 52

The Pharma Data

OCTOBER 27, 2021

Teva Pharmaceutical Industries Ltd. NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Teva Pharmaceutical Industries Ltd. About Teva.

Licensing 52

Licensing Licensing Disease Small Molecule 52

Drug Channels

OCTOBER 11, 2022

I am pleased to announce our new 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. examines how the Inflation Reduction Act could ultimately impact pharmaceutical wholesalers’ customers and business outlook.

Pharmaceuticals 74

Pharmaceuticals Biosimilars Licensing Licensing 74

Drug Discovery World

JULY 18, 2024

The UK has the potential to become the global leader in pharmaceutical cannabinoid R&D, according to a new report published by the Cannabinoid Research and Development Group (CRDG). The report argues that pharmaceutical cannabinoid R&D is in danger of being held back in the UK by “inappropriately excessive” regulation.

Science 130

Science Government Pharmaceuticals Regulations 130

Drug Discovery World

MARCH 28, 2024

Both Teva and Daichi Sankyo have been found to be in breach of the Association of the British Pharmaceutical Industry (ABPI) Code of Practice by the Prescription Medicines Code of Practice Authority (PMCPA).

Licensing 130

Licensing Licensing Pharmaceuticals Therapies 130

The Pharma Data

JANUARY 6, 2021

a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. ImaginAb will receive license fees and payments for manufacturing and other support. Working with leading pharmaceutical companies such as Pfizer, will help us achieve our goal.”

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

The Pharma Data

JUNE 14, 2023

Global Head of Research and Early Development for Oncology, Pharmaceuticals Division, Bayer AG. “We are excited to bring these highly innovative preclinical programs in-house that complement our early pipeline in precision oncology,” said Dominik Ruettinger, M.D.,

Licensing 40

Licensing Licensing Small Molecule Science 40

FDA Law Blog: Biosimilars

JANUARY 11, 2024

(HPM) Directors, Karla Palmer and Dara Levy , will present at the Puerto Rico Pharmaceutical Summit 2024, February 6, 2024, at the La Concha Renaissance San Juan Resort in San Juan, Puerto Rico.

Pharmaceuticals 59

Pharmaceuticals Compliance Licensing Licensing 59

Drug Discovery World

OCTOBER 2, 2023

INAQOVI, developed by Otsuka Pharmaceutical and Astex Pharmaceuticals, is the first oral hypomethylating agent to be licensed in the EEA in this patient population.

Treatment 130

Treatment Pharmacokinetics Clinical Trials Licensing 130

Drug Channels

OCTOBER 5, 2021

I am pleased to announce our new 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. The exhibits appear in all license versions. In some small way, I try to make the world a better and smarter place.

Pharmaceuticals 75

Pharmaceuticals Biosimilars Licensing Licensing 75

FDA Law Blog: Biosimilars

JUNE 17, 2024

Claud — FDA’s Office of Pharmaceutical Quality (OPQ) in the Center for Drug Evaluation and Research (CDER) is charged with assuring that drugs marketed in the U.S. Last week, OPQ released its 6th Annual Report on the State of Pharmaceutical Quality. to maintain its gold standard of pharmaceutical quality. By Kalie E.

Pharmaceuticals 59

Pharmaceuticals FDA Production Licensing 59

The Pharma Data

DECEMBER 16, 2020

–( BUSINESS WIRE )– Aurinia Pharmaceuticals Inc. NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Makoto Inoue, President and Representative Director of Otsuka Pharmaceutical Co., 17, 2020 09:00 UTC.

Licensing 52

Licensing Licensing Pharmaceuticals Disease 52

Drug Channels

OCTOBER 10, 2023

I am pleased to announce our new 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. we analyze the IRA’s likely consequences for wholesalers and the overall pharmaceutical business. In Subsection 6.5.1.,

Pharmaceuticals 40

Pharmaceuticals Specialty Pharmacies Pharmacy Biosimilars 40

Drug Discovery World

OCTOBER 4, 2023

The US Food and Drug Administration (FDA) has accepted Rocket Pharmaceuticals’ Biologics License Application (BLA) and granted Priority Review for RP-L201 (marnetegragene autotemcel).

FDA 130

FDA Therapies Pharmaceuticals Licensing 130

Collaborative Drug

JUNE 21, 2024

Burlingame, CA, June 21, 2024 — Collaborative Drug Discovery (CDD), a leading provider of data management solutions for the pharmaceutical and biotechnology industries, is pleased to announce the integration of iChemLabs' industry-leading IUPAC naming technologies into CDD Vault.

Licensing 58

Licensing Licensing Pharmaceuticals Drugs 58

Drug Discovery World

OCTOBER 21, 2022

Under an exclusive agreement, Jazz Pharmaceuticals will acquire development and commercialisation rights to Zymeworks’ zanidatamab across all indications and all territories except for those Asia/Pacific territories previously licensed by Zymeworks. billion, plus royalties on net sales.

Licensing 130

Licensing Licensing Treatment Pharmaceuticals 130

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA) granted Priority Review designation for the Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Pfizer Inc. Source link: [link].

Licensing 52

Licensing Licensing Vaccine FDA 52

Drug Discovery World

JUNE 1, 2023

6 Also in May 2023, Shanghai-native LaNova Medicines entered into an exclusive license agreement with AstraZeneca for LM-305, a pre-clinical stage ADC targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D).

Marketing 245

Marketing FDA Approval Licensing Licensing 245

Drug Discovery World

FEBRUARY 27, 2023

Under a new agreement, Destiny Pharma and Sebela Pharmaceuticals will co-develop NTCD-M3, Destiny’s lead asset for the prevention of Clostridioides difficile infection (CDI) recurrence. Patients who have taken NTCD-M3 were found to be protected from toxic strains of CDI.

Clinical Trials 130

Clinical Trials Licensing Licensing Drugs 130

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development. For more information, visit www.avantgen.com.

Licensing 52

Licensing Licensing Therapies Engineering 52

The Pharma Data

JANUARY 17, 2021

18 , 2021 /PRNewswire/ — Hanmi Pharmaceutical Co., In particular, two new drugs developed by Hanmi Pharmaceutical Co., In particular, two new drugs developed by Hanmi Pharmaceutical Co., and “Oraxol,” which was licensed out to Athenex, Inc. Hanmi Pharmaceutical Co.,

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

Drug Discovery World

OCTOBER 6, 2023

FDA acceptance advances investigational gene therapy The US Food and Drug Administration (FDA) has accepted Rocket Pharmaceuticals’ Biologics License Application (BLA) and granted Priority Review for RP-L201 (marnetegragene autotemcel).

Drugs 130

Drugs DNA Licensing Licensing 130

Drug Discovery World

JULY 2, 2024

City of Hope has granted an exclusive worldwide license to Osel for intellectual property on the novel use of CBM588 to enhance the efficacy of checkpoint inhibitors used to treat cancer, including metastatic renal cell carcinoma. Scientists from Osel and Miyarisan Pharmaceutical, the manufacturer of CBM588, collaborated on the study.

Trials 148

Trials Treatment Clinical Trials Licensing 148

Drug Discovery World

FEBRUARY 1, 2023

Michael Sassano , CEO at SOMAÍ Pharmaceuticals looks at what’s needed throughout Europe to help increase access to medicinal cannabis and the current state of pharmaceutical research in this area. However, the potential use of cannabis in a pharmaceutical setting is vast. The GW Pharmaceuticals purchase by Jazz for $6.7

Clinical Trials 130

Clinical Trials Trials Pharmaceutical Companies Doctors 130

Drug Discovery World

MARCH 27, 2023

Macomics and Ono Pharmaceutical have entered a worldwide drug discovery collaboration agreement to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer. Ono will have an exclusive option to license global rights to the candidates for further development and commercialisation.

Licensing 130

Licensing Licensing Drugs Pharmaceuticals 130

Drug Discovery World

SEPTEMBER 21, 2022

“Today’s EC approval of voclosporin represents a significant development for lupus nephritis patients in Europe, offering the appropriate patients a new treatment option,” said Andy Hodge, CEO of Otsuka Pharmaceutical Europe. .

Treatment 130

Treatment Licensing Licensing Pharmaceuticals 130

Drug Discovery World

JULY 13, 2023

NVIDIA will also help optimise and scale Recursion foundation models leveraging the NVIDIA AI stack and NVIDIA’s full-stack computing expertise. “Generative AI is a revolutionary tool to discover new medicines and treatments,” said Jensen Huang, founder and CEO of NVIDIA. “We

Drugs 130

Drugs Pharmaceutical Companies Licensing Licensing 130

Drug Discovery World

MAY 1, 2023

DDW’s Diana Spencer explores the European Commission’s proposed changes to EU pharmaceutical legislation, the reaction from industry and possible impact on smaller companies. The European Commission (EC) has proposed the largest reform to the EU’s pharmaceutical legislation in over 20 years.

Pharmaceuticals 130

Pharmaceuticals Packaging Clinical Trials Biosimilars 130

Drug Channels

SEPTEMBER 12, 2023

On October 10, 2023, Drug Channels Institute will release 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. pharmaceutical distribution industry. If you have any questions before purchasing a license to the report, please email me ( afein@drugchannels.net ). d/b/a Drug Channels Institute.

Pharmaceuticals 52

Pharmaceuticals Pharmacy Biosimilars Licensing 52

Drug Discovery World

AUGUST 23, 2022

The MMA was granted to Otsuka Pharmaceutical and Astex Pharmaceuticals’ oral fixed-dose combination of decitabine and cedazuridine (ASTX727). .

Treatment 130

Treatment Pharmacokinetics Clinical Trials DNA 130

BioPharma Drive: Drug Pricing

OCTOBER 20, 2023

The deal is worth up to $22 billion in total, making it one of the largest pharmaceutical licensing agreements by value.

Licensing 62

Licensing Licensing Pharmaceuticals Drugs 62

Drug Target Review

SEPTEMBER 5, 2024

This role gave me a good understanding of how important IP/patent and global marketing are for the brand but also the importance of emerging markets and co-development and out-licensing to other pharma companies. I experienced challenges in cultural differences working with US, UK, Japan, and China.

Pharma Companies 105

Pharma Companies Licensing Licensing Disease 105

Drug Discovery World

JANUARY 10, 2024

AIO-001 was exclusively licensed to Aiolos outside of Greater China by Jiangsu Hengrui Pharmaceuticals.

Pharmacokinetics 130

Pharmacokinetics Licensing Licensing Clinical Development 130

The Pharma Data

JANUARY 12, 2021

LONDON, UK / ACCESSWIRE / January 13, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully completed the development of its CDX antibody with a leading global pharmaceutical company (“GlobalCo”).

Pharmaceuticals 40

Pharmaceuticals Licensing Licensing Clinical Trials 40

The Pharma Data

JANUARY 21, 2021

–( BUSINESS WIRE )– Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on updated efficacy, safety, and dosing management of poziotinib from Cohorts 1 and 2 of the ZENITH20 clinical trial. About Spectrum Pharmaceuticals, Inc.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

Drug Discovery World

AUGUST 1, 2023

Partnerships Earlier this year cell-engineering company MaxCyte signed a strategic platform license (SPL) with biotechnology company Catamaran Bio. In return MaxCyte will receive platform licensing fees and program-related revenue.

Licensing 130

Licensing Licensing Drugs Engineering 130